Literature DB >> 23924786

CD40 therapy and surgery: a potential immunologic partnership.

Katelyn T Byrne1, Robert H Vonderheide.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23924786      PMCID： PMC3795345          DOI： 10.1097/CJI.0b013e31829fb871

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


× No keyword cloud information.
  32 in total

1.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.

Authors:  R R French; H T Chan; A L Tutt; M J Glennie
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

Authors:  E M Sotomayor; I Borrello; E Tubb; F M Rattis; H Bien; Z Lu; S Fein; S Schoenberger; H I Levitsky
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

3.  Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model.

Authors:  Maria R Sorensen; Peter J Holst; Maria A Steffensen; Jan P Christensen; Allan R Thomsen
Journal:  Vaccine       Date:  2010-08-02       Impact factor: 3.641

4.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Authors:  Robert H Vonderheide; Keith T Flaherty; Magi Khalil; Molly S Stumacher; David L Bajor; Natalie A Hutnick; Patricia Sullivan; J Joseph Mahany; Maryann Gallagher; Amy Kramer; Stephanie J Green; Peter J O'Dwyer; Kelli L Running; Richard D Huhn; Scott J Antonia
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

Authors:  S R Bennett; F R Carbone; F Karamalis; R A Flavell; J F Miller; W R Heath
Journal:  Nature       Date:  1998-06-04       Impact factor: 49.962

7.  Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.

Authors:  Connie Jackaman; Andrew M Lew; Yifan Zhan; Jane E Allan; Biljana Koloska; Peter T Graham; Bruce W S Robinson; Delia J Nelson
Journal:  Int Immunol       Date:  2008-09-29       Impact factor: 4.823

8.  Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

Authors:  Juliana Hamzah; Delia Nelson; Gerd Moldenhauer; Bernd Arnold; Günter J Hämmerling; Ruth Ganss
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

9.  Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Authors:  Jamie Honeychurch; Monique H M Melis; Simon J Dovedi; Lijun Mu; Timothy M Illidge
Journal:  Leuk Lymphoma       Date:  2013-02-18

10.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity.

Authors:  Timothy O'Sullivan; Robert Saddawi-Konefka; William Vermi; Catherine M Koebel; Cora Arthur; J Michael White; Ravi Uppaluri; Daniel M Andrews; Shin Foong Ngiow; Michele W L Teng; Mark J Smyth; Robert D Schreiber; Jack D Bui
Journal:  J Exp Med       Date:  2012-08-27       Impact factor: 14.307
View more
  3 in total

1.  β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.

Authors:  Mark J Bucsek; Guanxi Qiao; Cameron R MacDonald; Thejaswini Giridharan; Lauren Evans; Brian Niedzwecki; Haichao Liu; Kathleen M Kokolus; Jason W-L Eng; Michelle N Messmer; Kristopher Attwood; Scott I Abrams; Bonnie L Hylander; Elizabeth A Repasky
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

2.  Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.

Authors:  Jonas Rm Van Audenaerde; Elly Marcq; Bianca von Scheidt; Ashleigh S Davey; Amanda J Oliver; Jorrit De Waele; Delphine Quatannens; Jinthe Van Loenhout; Patrick Pauwels; Geert Roeyen; Filip Lardon; Clare Y Slaney; Marc Peeters; Michael H Kershaw; Phillip K Darcy; Evelien Ljm Smits
Journal:  Clin Transl Immunology       Date:  2020-08-15

Review 3.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.